triazavirin / Medsintez Pharma - LARVOL DELTA

Antiviral strategies against H5N1: current options and emerging therapeutics. (PubMed, Infection) - "This article provides a comprehensive, up-to-date overview of antiviral agents with established or investigational activity against H5N1, including both globally approved drugs and regionally licensed compounds, such as arbidol and triazavirin in Russia and laninamivir and favipiravir in Japan...The recent regulatory approvals of onradivir, suraxavir marboxil, and ZX-7101A in China are highlighted, along with emerging antivirals in advanced development...Challenges persist around resistance monitoring, access to novel therapies, and regulatory harmonization. Expanding the antiviral armamentarium through accelerated evaluation and integration of both traditional and innovative compounds will be essential to pandemic preparedness and effective H5N1 outbreak response."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives (PubMed, Ter Arkh) - "Riamilovir (trade name - «Triazavirin®») showed statistically significant prophylactic efficacy during its administration in an organized group. Its use decreased the frequency of detection of viral pathogens and resulted in milder acute respiratory disease, likely due to reduced viral load in individuals."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19. (PubMed, Future Sci OA) - P4 | "Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period. The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia. Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir. It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19 (PubMed, Ter Arkh) - "As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for the prevention of COVID-19 infection was established. It was shown that the relative risk of disease in the group taking riamilovir for prophylaxis was 88.96% lower than in the control group. Based on the results of a clinical trial, in October 2023 Ministry of Health of the Russian Federation approved the inclusion of a new indication (prophylaxis of COVID-19 infection) in the instructions for the medical use of the drug riamilovir (trade name - Triazavirin®)."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis. (PubMed, Int J Antimicrob Agents) - "A thorough evaluation of effectiveness, applicable to both mild-to-moderate and unstratified populations, highlights the specific advantages of proxalutamide, nirmatrelvir/ritonavir, triazavirin, azvudine, molnupiravir, and VV116 in combating COVID-19. Additional clinical data are required to confirm the efficacy and safety of simnotrelvir/ritonavir and leritrelvir. The safety profiles of these antivirals were deemed acceptable."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A new approach to etiotropic therapy ARVI in children (PubMed, Ter Arkh) - "As a result of the conducted clinical study, the high efficacy, safety and good tolerability of the drug riamilovir in the treatment of children aged 12-17 years with a diagnosis of ARVI was established. It is recommended to use the drug riamilovir in clinical practice as an etiotropic therapy in children aged 12-17 years with a diagnosis of ARVI due to its high efficacy and safety."

Clinical • Journal • Infectious Disease • Respiratory Diseases

The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences. (PubMed, Ceska Slov Farm) - "Thus, a primary aim of this review article was to provide more complex view on pharmacotherapeutic interventions based on TZV against COVID-19/SARS-CoV-2. The focus was on relevant results and conclusions from clinical trials as well as practical experiences with given antiviral agent considering not only real benefits of chosen therapeutic strategies but also several obstacles connected with them."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Triazavirin-A Novel Effective Antiviral Drug. (PubMed, Int J Mol Sci) - "Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug."

Journal • Review • CNS Disorders • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex. (PubMed, J Biomol Struct Dyn) - "favipiravir, remdesivir, EIDD, galidesivir, triazavirin, ruxolitinib, and baricitinib...The E of ML complexes better than -40.0 kcal/mol is observed for myricetin, fidarestat, protirelin, m-digallic acid, glucogallin, benserazide hydrochlorideseradie, remdesivir, tazobactum, sapropterin, nitrofurantoin, quinonoid, pyruvic acid calcium isoniazid, and aspartame, and among them the highest E -85.4 kcal/mol is observed for myricetin...The ONIOM-level study is found to be effective for the interpretation of the noncovalent interactions resulting from residues such as arginine, histidine, tyrosine, lysine, carboxylate, and amide moieties in the active site and suggests rational design strategies for COVID-19 drug development. Communicated by Ramaswamy H. Sarma."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Development of Drugs with Direct Antiviral Action Based on Azaheterocyclic Systems. (PubMed, Her Russ Acad Sci) - "This article discusses the results of studies carried out in recent years by a team of scientists from the Postovskii Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, in cooperation with the First President of Russia Boris Yeltsin Ural Federal University, Ural State Medical University, Volgograd State Medical University, and other scientific and production organizations of the country to create triazavirin (riamilovir) and other direct etiotropic antiviral drugs based on azaheterocyclic derivatives."

Journal

PHRUCov01: PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 (clinicaltrials.gov) - P2/3 | N=74 | Terminated | Sponsor: Wits Health Consortium (Pty) Ltd | N=420 ➔ 74 | Recruiting ➔ Terminated; DSMB report

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir ("Triazavirin®") active against SARS-CoV-2 (COVID-19). (PubMed, Org Biomol Chem) - "Therefore, the development of convenient methods for the synthesis of new derivatives of 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-one is always in demand. This review systematizes the information on the most common synthetic methods for constructing the 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-one heterocyclic system."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Antiviral drugs for coronavirus disease 2019 (COVID-19): A systematic review with network meta-analysis. (PubMed, Expert Rev Anti Infect Ther) - "Lopinavir (400mg)/ritonavir (100mg) significantly increased diarrhea, nausea and vomiting compared with placebo/no treatment and other antivirals, and was ranked worst for these outcomes while triazavirin (250mg), baloxavir marboxil (80mg), and remdesivir (100mg - 10days) ranked best, respectively. Cautious interpretations of the findings are however advised considering the paucity of the evidence. More RCTs are needed for a stronger evidence base."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 (clinicaltrials.gov) - P4; N=80; Recruiting; Sponsor: Ain Shams University

Clinical • New P4 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). (PubMed, Ceska Slov Farm) - "Since the beginning of the outbreak, a large number of clinical trials have been registered worldwide, and thousands of drugs have been investigated to face new health emergency of highly contagious COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The interactions between TZV and given viral structures or the ACE-2 receptor for SARS-CoV-2 might effectively block both the entry of the pathogen into a host cell and its replication. Promising treatment patterns of COVID-19 positive patients might be also based on a suitable combination of a membrane fusion inhibitor (umifenovir, for example) with viral RNA synthesis and replication inhibitor (TZV)."

Journal • CNS Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Antiviral drug Triazavirin, selectively labeled with H, C, and N stable isotopes. Synthesis and properties. (PubMed, Chem Heterocycl Compd (N Y)) - "The resulting H,C,N-Triazavirin was characterized by NMR spectroscopy. The online version contains supplementary material available at 10.1007/s10593-021-02927-1."

Journal

Small-molecule antiviral agents in ongoing clinical trials for COVID-19. (PubMed, Curr Drug Targets) - "These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Aerosol inhalation delivery of triazavirin in mice: outlooks for advanced therapy against novel viral infections. (PubMed, J Pharm Sci) - "Elimination rate constant determined in aerosol administration experiments was k = 0.077 min, which agrees with the value measured after intravenous delivery, but per-oral administration resulted in considerably lower apparent elimination rate constant of pseudo-first order, probably due to non-linear dependence of absorption rate on triazavirin concentration in gastrointestinal tract. The bioavailability of triazavirin aerosol is found to be 85%, which is about four times higher than for per-oral administration."

Journal • Gastrointestinal Disorder • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

PHRUCov01: PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 (clinicaltrials.gov) - P2/3; N=420; Recruiting; Sponsor: Fatima Mayat

Clinical • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. (PubMed, Engineering (Beijing)) - "Although no statistically significant evidence was found to indicate that Triazavirin benefits COVID-19 patients, our observations indicated possible benefits from its use to treat COVID-19 due to its antiviral effects. Further study is required for confirmation."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol. (PubMed, Engineering (Beijing)) - "Adverse events, serious adverse events, liver function, kidney function and concurrent treatments will be monitored and recorded throughout the trial. The results of this trial should provide evidence-based recommendations to clinicians for the treatment of COVID-19."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. (PubMed, Curr Mol Med) - "The interaction of TZV compound with the Coronavirus was performed by molecular docking studies. Therefore, TZV can be used for potential application against the Coronavirus 2019-nCoV."

Journal • Infectious Disease • Novel Coronavirus Disease